Home › Opioid Overdose › NCT04892251
Ketamine Assisted Psychotherapy for Opioid Use Disorder
RecruitingPhase 1/2
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Diagnosis of Opioid Use Disorder 2. Receiving OUD treatment with a buprenorphine formulation Exclusion Criteria: 1. Previous experience with a mindfulness-based intervention program 2. Pregnancy 3. Any serious medical, mental, or cognitive issue that prevents successful participation in a mindfulness-based group treatment program 4. Prior use of ketamine other than as prescribed by a physician 5. Any of the following medical conditions Blood Vessel Disease Heart Valve Disease Heart Failure Class 2 or Above Heart Disease Pregnancy/Breastfeeding Arteriovenous Malformation History of Intracranial Bleeding or Stroke History of Seizures Hypoxia defined by current need for supplemental oxygen Liver Disease History of allergic reaction to Ketamine Dementia (moderate-severe) History of Psychotic Disorder, Bipolar Disorder, or Personality Disorder Dissociative Identity Disorder
About the study
This pilot clinical trial aims to assess the preliminary efficacy of ketamine as an adjunct for a mindfulness-based intervention for opioid use disorder.
What is being tested
- MORE+KAP (combination product)
- MORE (behavioral)
Sponsor: University of Utah · Participants: 60 · Started: May 20, 2021
Contact the study team
- Research Coordinator · Phone: 801-581-3826
Official record on ClinicalTrials.gov — NCT04892251
Locations in the U.S.
| Utah | Center on Mindfulness and Integrative Health Intervention Development, Salt Lake City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.